IONS Latest Headlines

Ionis Pharmaceuticals: Buy Rating Reiterated on Strong Pipeline, Near-Term Catalysts, and Unchanged $110 Price Target

at www.tipranks.com (Fri, 5-Jun 1:25 PM)

Ionis Pharmaceuticals (IONS) Receives a Buy from Guggenheim

at www.tipranks.com (Fri, 5-Jun 1:05 PM)

Ionis Advances Alzheimer’s Research as Biogen’s Diranersen Shows Historic Reduction in Tau Pathology

Market Chameleon (Thu, 14-May 11:56 AM)

Biogen and Ionis Report First Phase 2 Evidence of Reducing Tau Pathology and Slowing Cognitive Decline in Early Alzheimer’s Disease

Market Chameleon (Thu, 14-May 7:32 AM)

Ionis Boosts 2026 Guidance as TRYNGOLZA Drives Revenue and Major Launches Approach

Market Chameleon (Wed, 29-Apr 9:37 AM)